2020 Fiscal Year Final Research Report
Identification of candidate target genes of tumor supressor KMT2D gene in esophageal cancer.
Project/Area Number |
19K18150
|
Research Category |
Grant-in-Aid for Early-Career Scientists
|
Allocation Type | Multi-year Fund |
Review Section |
Basic Section 55020:Digestive surgery-related
|
Research Institution | Osaka University |
Principal Investigator |
Odagiri Kazuki 大阪大学, 医学系研究科, 招へい教員 (30781794)
|
Project Period (FY) |
2019-04-01 – 2021-03-31
|
Keywords | 食道癌 / 化学療法 / KMT2D / epigenetic regulator |
Outline of Final Research Achievements |
This study clarified the relationship between KMT2D gene expression and susceptibility to chemotherapy in esophageal squamous epithelial cancer and the downstream gene regulated by KMT2D. We examined using a sample of patients with esophageal squamous cell carcinoma. Sensitivity to chemotherapy tended to decrease in the KMT2D low expression group. And the prognosis was also poor. In vitro assays, esophageal cancer cells that suppressed KMT2D expression had reduced sensitivity to chemotherapeutic agents. Experiments using the same cells suggested that the NF-1 gene and ERCC2 gene may be genes controlled by KMT2D. Previous reports say that these two genes are associated with chemosensitivity in other cancers. Thus, this study may help develop treatments for esophageal cancer.
|
Free Research Field |
食道癌
|
Academic Significance and Societal Importance of the Research Achievements |
本研究において、ESCCにおけるKMT2Dが制御している遺伝子の解明は今後の同遺伝子およびEpigenetic regulatorの機能解析の一助となると考えられる。また、臨床面においては治療開始前の腫瘍生検検体のKMT2Dの発現を調べることにより、発現低下例に対して化学療法薬に併用してKMT2D遺伝子の発現自体やその下流の遺伝子発現を制御する薬剤を使用することによって治療効果の改善が見込め、食道癌患者の予後改善に直結する。
|